http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109324143-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_89c0e841ebc3b867b6f3ae87ea71ea5d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-06 |
| filingDate | 2018-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19dfb073fea63b2e44b703c9dd8f33ed |
| publicationDate | 2019-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109324143-A |
| titleOfInvention | Method for preparing antibody related impurities by two-dimensional liquid phase separation |
| abstract | The present invention relates to a method for preparing relevant impurities of antibody products by utilizing two-dimensional liquid phase separation, wherein the antibody product is bevacizumab, comprising the following steps: (1) separation and purification by first-dimensional liquid chromatography; (2) Separation and preparation by second-dimension liquid chromatography: the fractions obtained by cutting the first-dimension liquid chromatography according to the retention time are drained to the second-dimension liquid chromatography for separation and preparation. The invention improves the recovery rate of bevacizumab-related impurities in the separation and preparation, greatly improves the efficiency, saves manpower, and improves the purity of the separated and prepared impurities. |
| priorityDate | 2018-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.